Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31687130 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2THRBLMNAHTTRXFP1 | |
| SCHEMBL6348438 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2THRBLMNAHTTTP53 | |
| SCHEMBL6752057 | 0.84 | KMT2A (0.51) | SMN1; SMN2LMNATP53TRIM24MEN1 | |
| SCHEMBL6342178 | 0.80 | CYP1A1 (0.50) | SMN1; SMN2THRBLMNATP53MAPT | |
| Antiarol SCHEMBL7467110 | 0.76 | CYP1A1 (0.46) | SMN1; SMN2THRBLMNATP53MAPT | |
| SCHEMBL6341219 | 0.76 | LMNA (0.79) | SMN1; SMN2LMNAHTTMAPTMEN1 | |
| SCHEMBL6341641 | 0.75 | THRB (0.53) | SMN1; SMN2THRBLMNAHTTTP53 | |
| SCHEMBL6350411 | 0.74 | HTR6 (0.65) | SMN1; SMN2THRBLMNAHTTTP53 | |
| SCHEMBL6048148 | 0.73 | CYP19A1 (0.65) | SMN1; SMN2LMNAHTT | |
| SCHEMBL28864522 | 0.73 | LMNA (0.68) | SMN1; SMN2THRBLMNAHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | claimed |
| EP-1181269-B1 | CELL PROLIFERATION INHIBITORS | ABBOTT LAB (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | claimed |
| US-20030078439-A1 | Process for the preparation of cell proliferation inhibitors | ABBVIE INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002024648-A2 | PROCESS FOR THE PREPARATION OF CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | claimed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | claimed |
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | disclosed |
| US-6924304-B2 | Cell proliferation inhibitors | ABBOTT LABORATORIES (US) | 2005-08-02 | — | — | US | disclosed |
| US-6710185-B2 | REACTING N-FORMYLINDOLINE WITH CHLOROSULFONIC ACID AND THIONYL CHLORIDE; AND REACTING THE PRODUCT WITH SODIUM BICARBONATE AND AN ANILINE COMPOUND | ABBOTT LABORATORIES | 2004-03-23 | — | — | US | disclosed |
| EP-1181269-B1 | CELL PROLIFERATION INHIBITORS | ABBOTT LAB (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030078439-A1 | Process for the preparation of cell proliferation inhibitors | ABBVIE INC. | 2003-04-24 | — | — | US | disclosed |
| US-6521658-B1 | Cell proliferation inhibitors | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| WO-2002024648-A2 | PROCESS FOR THE PREPARATION OF CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078439-A1 | Process for the preparation of cell proliferation inhibitors | MKI67, CCNI, CDKN1A | SMN1; SMN2 3964/4885THRB 2103/4885LMNA 1447/4885 |
| US-20030096856-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNA1 | SMN1; SMN2 1869/4885THRB 2495/4885LMNA 1086/4885 |
| US-20050187246-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNC | SMN1; SMN2 2093/4885THRB 2012/4885LMNA 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.